FDA advisers to weigh updated COVID vaccine targeting XFG subvariant

The Food and Drug Administration’s (FDA) advisory committee on vaccines this week will consider whether to change the COVID-19 vaccine to target the XFG subvariant for the upcoming 2026-2027 respiratory viral season. The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will meet on Thursday to discuss whether COVID-19 vaccines should target the NB.1.8.1…